WESTON,
Fla., May 28, 2024 /PRNewswire/ -- Cantex
Pharmaceuticals, Inc., a clinical stage pharmaceutical company
focused on developing transformative therapies for cancer and other
life-threatening medical conditions for which new treatments are
urgently needed, announced today that Cantex's azeliragon, a
well-tolerated once-a-day pill that inhibits "RAGE" (the receptor
for advanced glycation end products), will be featured in four
abstracts at this year's 2024 ASCO Annual Meeting to be held in
Chicago.
"The 2024 ASCO Annual Meeting represents an important
opportunity to meet with the leading oncology researchers from
around the world and showcase the progress of azeliragon clinical
investigations at leading cancer centers in several
difficult-to-treat cancers," said Stephen
G. Marcus, M.D., Cantex's Chief Executive Officer.
2024 ASCO Annual Meeting Abstracts:
Title: A phase I/II open label study to assess
safety and preliminary evidence of a therapeutic effect of
azeliragon in patients refractory to first-line treatment of
metastatic pancreatic cancer.
Abstract #: TPS4212
Title: Azeliragon, a RAGE inhibitor, in combination
with temozolomide and radiotherapy in patients with newly diagnosed
glioblastoma: Phase Ib/II CAN-201 NDG trial design.
Abstract #: TPS2096
Title: RAGE inhibition to decrease cancer therapy
related cardiotoxicity in women with early breast cancer
(RAGE).
Abstract #: TPS619
Title: A phase I/II study to assess safety and
preliminary evidence of a therapeutic effect of azeliragon combined
with stereotactic radiation therapy in patients with brain
metastases (ADORATION).
Abstract #: TPS2093
About Azeliragon
Azeliragon is an orally administered capsule, taken once daily,
that inhibits interactions of the receptor for advanced glycation
end products (known as RAGE) with certain ligands, including HMGB1
and S100 proteins in the tumor microenvironment. Azeliragon was
discovered by and originally under development for Alzheimer's
disease by vTv Therapeutics Inc. (NASDAQ: VTVT) from which Cantex
licensed worldwide rights to azeliragon. Clinical safety data from
these trials, involving more than 2000 individuals dosed for
periods up to 18 months, indicate that azeliragon is very well
tolerated.
Cantex has ongoing Phase II clinical trials in pancreatic
cancer, glioblastoma, brain metastasis, breast cancer, and a Phase
3 trial in hospitalized patients with pneumonia to prevent acute
kidney injury. These trials are based on azeliragon's robust
preclinical data as well as its extensive clinical safety
information from randomized placebo-controlled clinical trials.
Azeliragon has U.S. Food and Drug Administration (FDA) orphan
drug designation for the treatment of pancreatic cancer and
glioblastoma. FDA Orphan Drug Designation provides Cantex with
seven years of azeliragon marketing exclusivity from the time of
product launch for the orphan indication, and several other
important benefits, including assistance in the drug development
process, tax credits for clinical costs, and exemptions from
certain FDA fees.
About Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc. is a privately held, clinical stage
pharmaceutical company focused on developing transformative
therapies for cancer and other life-threatening medical conditions
for which new treatments are urgently needed. To learn more please
visit www.cantex.com.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical stage biopharmaceutical
company focused on developing oral, small molecule drug candidates,
led by cadisegliatin (TTP399), a potentially transformative
treatment for the reduction of hypoglycemic episodes in type 1
diabetes patients. To learn more please visit
vtvtherapeutics.com.
Contact Information:
Cantex Pharmaceuticals, Inc.
Stephen G. Marcus, M.D.
+1 954-315-3660
info@cantex.com
Juan F. Rodriguez
+1 954-315-3660
info@cantex.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel Kontoh-Boateng
+1 862-213-1398
dboateng@tiberend.com
Media
Casey McDonald
+1 646-577-8520
cmcdonald@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-announces-four-abstracts-to-be-presented-featuring-azeliragon-at-2024-asco-annual-meeting-302155456.html
SOURCE Cantex Pharmaceuticals, Inc.
